Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ketohexokinase isoform C (KHK-C) is the major isoform of ketohexokinase (fructokinase) responsible for hepatic fructose metabolism. It catalyzes the phosphorylation of fructose to fructose 1-phosphate, the first committed step in fructolysis. KHK-C is highly expressed in the liver and kidney, and its activity bypasses key regulatory steps in glycolysis, potentially contributing to increased lipogenesis and metabolic disorders. As such, KHK-C is considered a potential therapeutic target for the treatment of obesity, metabolic syndrome, and related conditions.
Inhibition of fructose phosphorylation, reduction of fructose 1-phosphate production
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ketohexokinase isoform C (KHK-C).